Sesen Bio (NASDAQ: SESN) is one of 515 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Sesen Bio to similar companies based on the strength of its institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.
This is a breakdown of current ratings and price targets for Sesen Bio and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sesen Bio Competitors||3438||10226||23738||758||2.57|
Sesen Bio currently has a consensus target price of $3.75, indicating a potential upside of 63.76%. As a group, “Pharmaceutical preparations” companies have a potential upside of 38.41%. Given Sesen Bio’s stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than its competitors.
Institutional & Insider Ownership
52.0% of Sesen Bio shares are held by institutional investors. Comparatively, 47.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 21.0% of Sesen Bio shares are held by company insiders. Comparatively, 15.1% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Sesen Bio and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sesen Bio||$430,000.00||-$29.02 million||-2.06|
|Sesen Bio Competitors||$2.01 billion||$135.62 million||-9.27|
Sesen Bio’s competitors have higher revenue and earnings than Sesen Bio. Sesen Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Sesen Bio has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, Sesen Bio’s competitors have a beta of 0.95, meaning that their average share price is 5% less volatile than the S&P 500.
This table compares Sesen Bio and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sesen Bio Competitors||-2,954.13%||-95.94%||-28.36%|
Sesen Bio beats its competitors on 9 of the 13 factors compared.
Sesen Bio Company Profile
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.